Novo Nordisk said Monday that its experimental next-generation drug, CagriSema, produced an estimated average weight loss of 12.4% in a late-stage trial of patients with type 2 diabetes, beating Eli Lilly's rival drug Mounjaro in a head-to-head comparison. You can read the details in Reuters' coverage here.

Before anything else, let me explain what CagriSema actually is, because the name alone won't tell you much. It combines two things: cagrilintide, which mimics a gut hormone called amylin that slows digestion and dampens appetite, and semaglutide, the active ingredient in Ozempic and Wegovy, which works through the GLP-1 pathway. The idea is that hitting two appetite and metabolism signals at once gets you more effect than either alone. Lilly took the same approach with tirzepatide, which pairs GLP-1 with a second hormone called GIP and is sold as Zepbound and Mounjaro.

In this trial, the head-to-head apparently favored Novo's combination in people with diabetes. That matters because weight loss in patients with type 2 diabetes is famously harder to achieve than in people without it. Blood sugar medications, insulin resistance, and the disease itself all push back against the scale. So a 12.4% average loss in this population is a genuinely strong number.

Now for my caveats, and yes, I have some.

First, that 12.4% figure is an estimated average. These results come from a company press release ahead of full publication, and drug makers have a long history of headline numbers that shift slightly once the peer-reviewed paper lands. I've only read the coverage, not the full trial data, and I want to see the dropout rates, the side effect profile, and how many patients actually hit target weight before I call this settled.

Second, safety deserves the same attention as efficacy, especially in this group. Patients with type 2 diabetes tend to have higher rates of depression to begin with, so these are people who warrant careful monitoring of mood and mental health outcomes alongside the weight numbers. I'd want to see how the trial tracked and reported those outcomes before drawing any conclusions.

And third, weight loss is a means, not an end. The number I'll be watching for when the full data come out is what happened to these patients' blood sugar control, blood pressure, and cardiovascular risk. A drug that helps people with diabetes shed weight and also protects their hearts over the long term, that's the real prize.

Having covered this space for a while now, I'll admit the pace startles me a little. It wasn't long ago that single-hormone drugs were the headline makers. Now companies are stacking hormones like ingredients in a recipe, and the combinations keep one-upping each other. My son Linton jokes that I read these trial results the way other people read sports scores. Fair, probably.

One thing I'd gently remind everyone: these medications work best alongside the boring fundamentals, movement, decent sleep, protein, strength training. They're powerful tools, and for people with diabetes carrying extra weight, a better tool could be genuinely life-changing. But a 12.4% average still hides individual variation, and nobody should feel like a failure if their number looks different.

The full results should be presented at a medical conference and published in a journal before too long. When they are, I'll dig into the actual paper rather than the press release, and I'll let you know whether the headline holds up. That's the deal I always make with these stories, and this one is no exception.